DUBLIN, Nov 30, 2018 /PRNewswire/ --
The "Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.com's offering.
The Neuroendocrine Tumors (NETs) - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of NETs in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
The report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Neuroendocrine Tumors from 2016 to 2027 segmented by seven major markets. The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Study Period: 2016-2027
Neuroendocrine Tumors (NETs) - Disease Understanding and Treatment Algorithm
The DelveInsight Neuroendocrine Tumors market report gives the thorough understanding of the NETs by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Neuroendocrine Tumors in the US, Europe, and Japan.
Neuroendocrine Tumors Epidemiology
The Neuroendocrine Tumors epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [total prevalent cases, total incident cases, diagnosed prevalent cases, symptom based classification of NETs (asymptomatic and symptomatic), diagnosed prevalence based on malignancy (Malignant and non-malignant), site specific incident cases (Gastroenteropancreatic, lung and other sites), Grade-wise prevalent cases (Grade I, Grade II and Grade III) and stage-wise prevalent cases (localized, regional and distant)] scenario of Neuroendocrine Tumors (NETs) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.
The total prevalent population of Neuroendocrine Tumors (NETs) was found to be 442,100 in the year 2016 in 7MM.
Neuroendocrine Tumors Drug Chapters
This segment of the NETs report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Medications, including chemotherapy and cytotoxic agents are considered after surgery for NETs treatment. The somatostatin analogs, octreotide and lanreotide remain the keystone of treatment. Cytotoxic therapies such as streptozocin, 5-FU, or temozolomide are considered in the palliation of patients with advanced pancreatic NET and symptoms related to tumor bulk.
For the distant tumors that have grown outside where regional therapies don't work, systemic therapies are the options for treatment, Everliomus is an effective targeted therapy that acts as mTOR inhibitor, sunitinib is the only orally available tyrosine kinase inhibitor and radiolabeled somatostatin analog therapies are generally considered.
Detailed chapter for upcoming therapies like Azedra (Progenics Pharmaceuticals), 177Lu-edotreotide PRRT (ITM Isotopen Technologien Muenchen), Sulfatinib (Hutchison MediPharma), Axitinib (Pfizer), RRx-001 (EpicentRx), Entrectinib (Ignyta), AMG-479 (Amgen), Carfilzomib (Amgen), ATG-008 (Antengene) and Fosbretabulin (Mateon Therapeutics) have been covered in the report.
Neuroendocrine Tumors Market Outlook
The Neuroendocrine Tumors market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market of Neuroendocrine Tumors in 7MM was found to be USD 3.45 billion in 2016.
Neuroendocrine Tumors Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Key Topics Covered:
1. Key Insights
2. Neuroendocrine Tumors Epidemiology Overview at a Glance
- Market (%) Distribution of Neuroendocrine Tumors in 2017
- Market (%) Distribution of Neuroendocrine Tumors in 2027
3. Disease Background and Overview: Neuroendocrine Tumors (NET)
- Classification of Neuroendocrine Tumors
- Risk Factors
- Grading of NETs
- Staging of NETs
4. Epidemiology and Patient Population
- Key Findings
- 7MM Total Prevalent Patient Population of NETs
- Total Incident Patient Population of NETs
- Country Wise-Epidemiology of NETs
- United States
- EU5 Countries
- United Kingdom
5. Treatment Algorithm
6. Unmet needs
7. Marketed drugs
- Afinitor (Everolimus): Novartis
- Sutent (Sunitinib Malate): Pfizer
- Somatuline Depot (Lanreotide): Ipsen Biopharmaceuticals Inc.
- Lutathera (lutetium Lu 177 dotatate): Advanced Accelerator Applications S.A.
8. Emerging drugs
9. Key Cross Competition
- Iobenguane I-131: Progenics Pharmaceuticals
- 177Lu-edotreotide PRRT: ITM Isotopen Technologien Muenchen
- AMG 479: Amgen
- Anlotinib: Advenchen Laboratories
- Carfilzomib: Amgen
- ATG-008: Antengene
- Entrectinib: Ignyta
- Fosbretabulin: Mateon Therapeutics
- Ipilimumab: Bristol-Myers Squibb
- Ribociclib: Novartis
- Pembrolizumab: Merck
- RRx-001: EpicentRx
- Axitinib: Pfizer
- Cabozantinib: Exelixis
- CAM2029: Camurus
- Atezolizumab and Bevacizumab: Genentech
- Lenvatinib: Eisai
- Pasireotide LAR: Novartis
- Spartalizumab: Novartis
- Tirapazamine: Teclison
- Pentarin: Tarveda Therapeutics
- Sulfatinib: Hutchison MediPharma
- Ibrutinib: Pharmacyclics
- Ramucirumab: Eli Lilly
- ALT 803: Altor Biosciences
- Talimogene laherparepvec: Amgen
- Netazepide: Trio Medicines
10. Neuroendocrine Tumors: 7 Major Market Analysis
- Key Findings
- Market Size of Neuroendocrine Tumors (NETs) in 7MM
- Market Outlook by Country
11. Market Drivers
12. Market Barriers
- Advanced Accelerator Applications S.A.
- Advenchen Laboratories
- Altor Biosciences
- Bristol-Myers Squibb
- Eli Lilly
- Hutchison MediPharma
- Ipsen Biopharmaceuticals Inc.
- ITM Isotopen Technologien Muenchen
- Mateon Therapeutics
- Progenics Pharmaceuticals
- Tarveda Therapeutics
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5v6x6f/global?w=5
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets